UA5153U - Method for preventing viral diarrhea of the cattle - Google Patents

Abstract

The method for preventing the viral diarrhea of the cattle comprises the injection of the live vaccine prepared of the modified strain "VC-1 V-1N" adapted to the transplantable cell cultures (coronary vessels of the calf, trachea of the calf, the kidney of the sheep). The vaccine is injected in a volume of 2 ml intramuscularly twice with two-week interval. Separately, at the same time the alkaline hydrolysate of Bac. alvei is injected intramuscularly in a volume of 1 ml as immunostimulator.

Description

The proposed useful model relates to virology, namely the production of vaccines in biological industries and the prevention of viral diarrhea in cattle.

The method of prevention of viral diarrhea-a disease of the mucous membranes of cattle, is intended for the prevention of viral diarrhea (VD) by vaccination of young cattle (cattle), beef cows and non-calves.

The main consumers of the vaccine are farms where there is cattle.

There are vaccines for the prevention of VD: (Belyavskaya T.V. "Bivalent vaccine against infectious rhinotracheitis and viral diarrhea of cattle", author's abstract of the dissertation for the degree of Candidate of Veterinary Sciences, Minsk - 1998, Academy of Agricultural Sciences, Republic of Belarus; Belarusian Scientific and Research Institute of Experimental Veterinary Medicine named after S.N. Vyshelessskyi); ("Live vaccine from an attenuated strain (KIT 4350) VD-

BOS" Syurin V.N., Samuylenko A.Ya., Solov'ev B.V., Fomina N.V. Viral diseases of animals / Moscow, VNITYBP, 1998, p.154).

For the prevention of viral diarrhea, there is a "Live vaccine against viral diarrhea - diseases of the mucous membranes of cattle and a method for the prevention of viral diarrhea - diseases of the mucous membranes of cattle". Moscow) - this solution is a prototype.

The disadvantage of this solution is that the vaccine contains a Russian strain. The basis of a useful model is the task of developing a method of prevention of viral diarrhea in cattle, which includes the introduction of a live vaccine by using a live vaccine from a modified strain "VK-18-1M", adapted to transplanted cell cultures (coronary vessels of a calf, trachea of a calf, kidneys of a sheep) internally ulcer twice with an interval of 14 days in a dose of 2 cm3 and with a separate simultaneous intramuscular injection of an immunostimulator (alkaline hydrolyzate of Vas. aimei) in a dose of 1 cm3 to ensure the process of prevention of viral diarrhea of cattle.

The vaccine is prepared from the "VK-18-1M" strain of the diarrhea virus, which is adapted to transplantation cultures of cells of the coronary vessels of a calf, trachea of a calf, and kidney of a sheep. The vaccine is freeze-dried in a protective medium (mixture of sucrose and gelatin).

The composition of the vaccine:

Antiviral liquid with diarrhea virus "VK 1 V-1 M" with a titer of 6-7 Id. ТСД5BO/ml, sucrose, gelatin, penicillin, streptomycin, and alkaline hydrolyzate Vas is used as an immunostimulator. Aimei (LPS).

The vaccine is administered twice with an interval of 14 days in a dose of 2 cm3 intramuscularly with a simultaneous separate intramuscular injection of an immunostimulator in a dose of 1 cm3.

Example 1.

To check the quality of the vaccine, a sample was taken from different places of each series in the amount specified in the formula

Her -OA/M de

P - the number of packages required for control (sample volume);

M - the number of packages in the series.

From the sample, 6 vials of the drug were selected by random selection, 3 of which were used for the test, the remaining 3 vials were sent to the archive of the VBK controller for storage for 18 months.

The samples that were sent to the controller's archive were sealed and accompanied by a document of the prescribed form, which indicated: the name of the drug, the date of manufacture, the batch number, the date of sampling, the total number of units in the package, the net weight, the position and signature of the person who took the sample, and designation of these TU U, position, signature of the person who took the samples, archival samples were stamped "Archives".

In case of unsatisfactory test results for at least one of the indicators, repeated tests were carried out on a double number of samples from the same series and on a double number of animals. The results of repeated tests were considered final and applied to the entire series. In case of receiving unsatisfactory results of repeated tests, the series of the drug was considered as not meeting the requirements of the technical specifications. It was missing and destroyed.

Example 2.

The appearance, color, violation of the tightness of the vials were determined. The vaccine was a dry, porous mass of pink color (leophilic dried). The vials with the vaccine were carefully sealed, without cracks.

Example 3.

Determination of contamination by bacterial and fungal microflora was carried out in accordance with GOST 28085-89 "Biological preparations. Methods of bacteriological control of sterility".

Three vials of vaccine were used to study mycoplasma contamination. The vaccine in each vial was dissolved in distilled water in a volume corresponding to the initial volume before drying. The vaccine from each vial was combined in one sterile container and seeded in 0.53 cm C tubes with semi-liquid (0.395 agar) and thick (1.395 agar) Edward's medium, the basis of which is a tryptic digest of bovine heart muscle with the addition of 1095 yeast extract, 2095 normal horse serum (without preservative) and 100 units of penicillin per 1 cm3 of medium.

Three consecutive passages were conducted. The crops were kept at (37-38)"C for 7 days. The vaccine was not contaminated with bacterial, fungal microflora and mycoplasmas.

Example 4.

Definition of harmlessness.

C vials with vaccine were used for research. After dissolution, they were combined in one sterile vial, shaken and used for research. The vaccine was administered to 10 white mice subcutaneously at 0.2 cm3. The vaccine did not cause disease and death of mice during 10 days of observation, which confirms its harmlessness.

Example 5.

Determination of immunogenicity.

The vaccine from 3 vials (after dissolution) was combined in one sterile vial and injected intramuscularly into the thigh of five guinea pigs at a dose of 2 cm3. After 14 days, repeated vaccination was carried out, and after 28 days, blood serum was obtained from the animals. Blood serum samples from each animal in an equal ratio were combined in one container and studied in a neutralization reaction with the bovine diarrhea virus (strain "VK-18-1M") in vitro cultures of calf kidney cells.

The vaccine was considered to have passed control if antibodies to the VD virus were detected in the blood serum of vaccinated guinea pigs in the neutralization reaction in titers of not less than 1:16.

Example 6.

The dynamics of titers of specific antibodies in calves after the introduction of test samples of live vaccine against Viral diarrhea and immunostimulant is presented in the table.

The process of prevention of viral diarrhea of cattle will ensure sufficient immune protection of animals.

Table xx of diarrhea strain "VK-1V-1M" lys (number of heads) before administration / 4 Lib Lislia of the SECOND ryrist ---- - before administration of antibodies

Me| dose (cm)) | dose (cm?) | number of heads| input 17771175 77711717 -11111717711115 | lard | lard | 30 Krkh 2 777772. 7777177 1117771115 | 35505 | 5254025 | 75 4, 77 -7771171771717171717711171711115 | 20-05 | 3255025 | 1.95 5| Kontvol// | (:YKfB OO | 7 15 | 253025 | 253025 | -

Claims (1)

The method of prevention of viral diarrhea of cattle, which includes the introduction of a live vaccine, which differs in that it uses a live vaccine from a modified strain "VK-I V-IM", adapted to transplantable cell cultures (coronary vessels of a calf, trachea of a calf, kidneys of a sheep) with a two-time introduction intramuscularly with an interval of 14 days in a dose of 2 cm" and separately simultaneously injecting an alkaline hydrolyzate intramuscularly Vas.aiuei in a dose of 1 cm" as an immunostimulant.